Harrow Health Inc (HROW)
Healthcare
Drug Manufacturers - Special
44.50 $
Closing price · As of: 20. Jul 2026
🔔 Watch stock
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Breakout & Setup
Momentum & Trend
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Market Cap
The value of the entire company on the market: share price times total shares outstanding.
1.5Mrd. $
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
37Mio.
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
75.9%
Beta
Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market.
0.3
Performance
Perf. 1M
Price performance over the last month.
16.30%
Perf. 3M
Price performance over the last 3 months.
21.60%
Perf. 6M
Price performance over the last 6 months.
-18.00%
YTD Performance (%)
Price performance since the start of the year (Year to Date).
-12.70%
52-Week-High Distance
How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high.
-24.3%
Valuation
P/E
Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.
–
Forward P/E
P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future.
285.7
PEG
P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.
–
P/B
Price-to-book ratio: market value relative to book equity.
54.6
P/S
Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable.
5.7
EV/EBITDA
Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero.
55.3
Price/FCF
Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.
107.8
Profitability
Gross Margin
Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power.
74.1%
EBIT Margin
EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes.
–
Net Margin
Net margin: what's left of sales as profit after ALL costs, interest, and taxes.
-5.6%
Return on Equity
Return on equity: how much profit does the company generate per year on shareholders' equity?
-35.4%
Return on Assets
Return on assets: how much profit the company generates from its total assets (equity and debt combined).
3.1%
Balance Sheet & Safety
Equity Ratio
Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet.
–
Debt/Equity
Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity.
10.5
Altman Z
Edward Altman's bankruptcy early-warning score: under 1.8 = danger zone, over 3 = safe. Values well above that mean a very resilient balance sheet.
4.20
weak
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
2 von 9
Growth
Sales Growth Last Quarter
Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY).
-7.60%
EPS Growth Last Quarter
Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY).
-10.30%
Sales Growth (Year)
Sales growth in the last fiscal year versus the year before.
36.41%
Forward Sales Growth
Sales growth analysts expect over the next 12 months — an estimate, not a guarantee.
48.01%
Forward EPS Growth
Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee.
–
Quality & Screener
Stage
Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line.
3
RS Rating
Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks.
58
EPS Rating
Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth.
26
weak
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
2 von 9
Fundamental Rating
Our own Fundamental Rating from −100 to +100 with an A+ to F grade: growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety, all percentile-ranked.
D (-29 von 100)
Altman Z
Edward Altman's bankruptcy early-warning score: under 1.8 = danger zone, over 3 = safe. Values well above that mean a very resilient balance sheet.
4.20
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.19 | – | 67 | 83.80 | 10.10 | -18 | -55 |
| 2025: Q1 | -0.50 | – | 48 | 38.30 | -37.20 | 20 | 20 |
| 2025: Q2 | 0.13 | – | 64 | 30.20 | 7.80 | -1 | -1 |
| 2025: Q3 | 0.03 | – | 72 | 45.40 | 1.40 | 17 | 16 |
| 2025: Q4 | 0.18 | -4.80 | 89 | 33.30 | 7.40 | 8 | 8 |
| 2026: Q1 | -0.74 | – | 44 | -7.60 | -62.40 | -9 | -9 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Harrow, Inc., ein Augenheilkunde-Pharmaunternehmen, beschäftigt sich mit der Entdeckung, Entwicklung und Vermarktung ophthalmologischer Pharmaprodukte in den USA.
| Employees | 373 |
|---|---|
| Headquarters | Nashville, TN |
| Website | harrow.com |
| IPO Date | 28. Sep 2007 |
| Next Earnings | 10. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Mark L. Baum J.D. | CEO, Chairman of the Board & Founder | 1972 |
| Andrew R. Boll C.F.A., C.M.A. | President, CFO & Corporate Secretary | 1982 |
| Amir W. Shojaei Ph.D., Pharm.D. | Chief Scientific Officer | 1968 |
| Francis W. Mullery | President & CEO of Harrow's ImprimisRx Division | – |
| Randall E. Pollard | Chief Accounting Officer | 1972 |
| Michael D. Biega | Vice President of Investor Relations & Communications | – |
| Brett A. Burrell | Vice President of Legal & Compliance | – |
| Kim Barratt | Chief Talent Officer | – |
| Mark A. Mannebach Ph.D., R.Ph. | Head of Regulatory Affairs & Pharmacovigilance | – |
| Prashanth S. Annavajjhala | Chief of Staff | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.